SciELO - Scientific Electronic Library Online

 
vol.138 número1Pinzamiento femoroacetabular: Conceptos básicos en una nueva causa de dolor inguinalLos diagnósticos de Gerard de Nerval: La influencia de la locura en la genialidad literaria índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

Compartir


Revista médica de Chile

versión impresa ISSN 0034-9887

Resumen

CASELLI M, GINO; PINEDO M, GEORGE; ZUNIGA D, ÁLVARO  y  ALVAREZ L, MANUEL. Active and refractory ulcerative proctitis: An update. Rev. méd. Chile [online]. 2010, vol.138, n.1, pp.109-116. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872010000100016.

Ulcerative colitis (UC) is a chronic inflammatory disease of unknown etiology that affects a variable length of the colon, starting from the rectum. When the disease is confined to the rectum is called ulcerative proctitis (UP). Several studies have unsuccessfully attempted to determine the factors that determine the extent of involvement. The goals of therapy in UP are to induce and maintain remission of symptoms and disease. Topical treatment with 5-aminosalicylates (5-ASA) is the treatment of choice to induce remission. In the maintenance phase, long-term follow up studies suggest that treatment with 5-ASA is better than placebo, to maintain the disease inactive. For those patients that do not respond to treatment with topical 5-ASA or have a moderate to severe disease, there are additional therapies such as oral 5-ASA, topical or systemic corticosteroids, immunomodulators, biological therapies (Infliximab) and cyclosporine. Surgery is seldom needed.

Palabras clave : Colitis; ulcerative; meselamine; proctitis.

        · texto en Español     · Español ( pdf )